Stock listing
NASDAQ:CCXI ChemoCentryx Inc. Stock
Home listing (NASDAQ) of ChemoCentryx Inc.
Follow ChemoCentryx Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CCXI
$11.26 USD +0.57 (+5.3%)
Close on Nov 4, 2026
- Day range
- $10.81 – $12.17 USDNov 4, 2026
- Volume
- 4.78M sharesNov 4, 2026
- Market cap
- $471.8M USDAt the close on Nov 4, 2026 · price × 41.90M shares outstanding
- Traded on an average day
- $36.99M USDMedian day 2.39M shares · last 3 months, Aug 4, 2026 – Nov 4, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CCXI · Home | $11.26 USD | +0.57 (+5.3%) | 4,782,294 | $11.03 | $12.17 | $10.81 | $10.69 | Close on Nov 4, 2026 |
| NASDAQ:CCXIU | $11.99 USD | +1.29 (+12.1%) | 383 | $11.69 | $11.99 | $11.69 | $10.70 | Close on Nov 4, 2026 |
Daily closes
Last 3 months, Aug 4, 2026 – Nov 4, 2026 · NASDAQ:CCXI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $11.26 | +0.57 | +5.3% | $11.03 | $12.17 | $10.81 | 4,782,294 | |
| $10.69 | +1.40 | +15.1% | $9.50 | $10.97 | $9.40 | 4,442,019 | |
| $9.29 | +1.14 | +14.0% | $8.37 | $9.68 | $8.004 | 2,222,867 | |
| $8.15 | -1.79 | -18.0% | $9.43 | $9.43 | $8.05 | 4,211,381 | |
| $9.94 | -0.31 | -3.0% | $10.00 | $10.43 | $9.59 | 4,072,773 | |
| $10.25 | +0.01 | +0.1% | $10.24 | $10.26 | $10.22 | 4,859,545 | |
| $10.24 | -0.01 | -0.1% | $10.24 | $10.25 | $10.21 | 11,677,043 | |
| $10.25 | -0.01 | -0.1% | $10.25 | $10.27 | $10.24 | 7,244,600 | |
| $10.26 | -0.005 | 0.0% | $10.26 | $10.29 | $10.26 | 2,620,643 | |
| $10.27 | -0.085 | -0.8% | $10.30 | $10.32 | $10.25 | 8,688,440 | |
| $10.35 | -0.005 | 0.0% | $10.38 | $10.50 | $10.31 | 2,435,975 | |
| $10.36 | -0.125 | -1.2% | $10.52 | $10.61 | $10.34 | 4,008,345 | |
| $10.48 | -0.18 | -1.7% | $10.76 | $10.78 | $10.46 | 1,547,826 | |
| $10.66 | -0.69 | -6.1% | $11.19 | $11.28 | $10.50 | 3,558,600 | |
| $11.35 | +0.52 | +4.8% | $10.65 | $11.40 | $10.53 | 2,839,900 | |
| $10.83 | -0.33 | -3.0% | $10.95 | $11.21 | $10.64 | 3,619,400 | |
| $11.16 | +0.38 | +3.5% | $10.71 | $11.35 | $10.71 | 2,581,100 | |
| $10.78 | -0.15 | -1.4% | $10.82 | $10.84 | $10.65 | 2,110,300 | |
| $10.93 | -0.11 | -1.0% | $11.12 | $11.14 | $10.90 | 1,347,100 | |
| $11.04 | -0.20 | -1.8% | $11.53 | $11.60 | $10.96 | 2,922,800 | |
| $11.24 | -0.69 | -5.8% | $11.60 | $11.70 | $11.18 | 2,166,900 | |
| $11.93 | -0.14 | -1.2% | $12.28 | $12.40 | $11.09 | 7,114,800 | |
| $12.07 | +0.08 | +0.7% | $12.08 | $12.09 | $11.71 | 1,572,400 | |
| $11.99 | +0.37 | +3.2% | $11.80 | $12.15 | $11.71 | 2,131,500 | |
| $11.62 | 0.00 | 0.0% | $11.72 | $11.78 | $11.46 | 1,777,600 | |
| $11.62 | -0.71 | -5.8% | $12.33 | $12.33 | $11.51 | 3,213,900 | |
| $12.33 | +0.28 | +2.3% | $12.15 | $12.75 | $11.81 | 3,721,700 | |
| $12.05 | -0.38 | -3.1% | $12.20 | $12.31 | $12.04 | 982,100 | |
| $12.43 | +0.20 | +1.6% | $12.28 | $12.45 | $12.08 | 1,478,200 | |
| $12.23 | -0.49 | -3.9% | $12.38 | $12.49 | $12.05 | 2,176,300 | |
| $12.72 | -0.42 | -3.2% | $13.08 | $13.08 | $12.37 | 1,083,400 | |
| $13.14 | -0.44 | -3.2% | $13.50 | $13.63 | $12.91 | 1,766,300 | |
| $13.58 | +0.68 | +5.3% | $13.03 | $13.64 | $12.81 | 2,363,400 | |
| $12.90 | +0.82 | +6.8% | $12.13 | $13.03 | $12.13 | 2,986,400 | |
| $12.08 | -0.01 | -0.1% | $12.59 | $12.69 | $11.97 | 2,407,900 | |
| $12.09 | +0.04 | +0.3% | $12.25 | $12.59 | $11.76 | 2,459,900 | |
| $12.05 | +0.05 | +0.4% | $12.03 | $12.50 | $11.77 | 4,568,500 | |
| $12.00 | -0.32 | -2.6% | $12.13 | $12.28 | $11.80 | 3,531,000 | |
| $12.32 | -0.49 | -3.8% | $12.95 | $13.00 | $12.24 | 2,475,400 | |
| $12.81 | -0.39 | -3.0% | $13.00 | $13.12 | $12.80 | 1,349,300 | |
| $13.20 | -0.40 | -2.9% | $13.50 | $13.90 | $13.17 | 1,675,500 | |
| $13.60 | +0.20 | +1.5% | $13.36 | $14.16 | $13.10 | 1,738,600 | |
| $13.40 | -0.42 | -3.0% | $13.88 | $13.90 | $13.33 | 945,900 | |
| $13.82 | +0.56 | +4.2% | $13.83 | $14.15 | $13.67 | 2,027,000 | |
| $13.26 | +0.21 | +1.6% | $13.22 | $13.59 | $13.15 | 923,400 | |
| $13.05 | -0.33 | -2.5% | $13.10 | $13.36 | $13.00 | 1,319,400 | |
| $13.38 | -0.59 | -4.2% | $13.94 | $13.97 | $13.27 | 1,545,200 | |
| $13.97 | -0.44 | -3.1% | $14.37 | $14.49 | $13.66 | 1,722,600 | |
| $14.41 | -0.41 | -2.8% | $14.94 | $14.97 | $14.33 | 966,800 | |
| $14.82 | +0.37 | +2.6% | $14.47 | $14.84 | $14.05 | 811,100 | |
| $14.45 | +0.36 | +2.6% | $14.30 | $14.66 | $14.00 | 1,130,300 | |
| $14.09 | -0.48 | -3.3% | $14.11 | $14.33 | $13.81 | 1,789,700 | |
| $14.57 | +0.50 | +3.6% | $14.50 | $14.86 | $13.88 | 1,813,100 | |
| $14.07 | -0.53 | -3.6% | $14.50 | $14.66 | $13.99 | 2,161,500 | |
| $14.60 | -1.05 | -6.7% | $16.48 | $16.48 | $14.33 | 6,892,200 | |
| $15.65 | -1.55 | -9.0% | $16.51 | $16.96 | $15.51 | 4,149,900 | |
| $17.20 | +0.13 | +0.8% | $17.87 | $18.48 | $17.12 | 5,768,100 | |
| $17.07 | +0.88 | +5.4% | $16.63 | $17.07 | $15.60 | 3,282,600 | |
| $16.19 | 0.00 | 0.0% | $16.19 | $16.89 | $15.54 | 2,332,600 | |
| $16.19 | -0.18 | -1.1% | $16.75 | $16.75 | $16.02 | 1,790,400 | |
| $16.37 | +0.27 | +1.7% | $17.00 | $17.59 | $16.24 | 3,477,000 | |
| $16.10 | -0.52 | -3.1% | $16.61 | $16.66 | $15.91 | 1,363,000 | |
| $16.62 | +0.22 | +1.3% | $16.93 | $16.99 | $16.36 | 1,891,300 | |
| $16.40 | +0.47 | +3.0% | $15.05 | $16.98 | $15.01 | 3,893,400 | |
| $15.93 | +0.53 | +3.4% | $15.50 | $16.24 | $14.60 | 3,952,500 | |
| $15.40 | -0.07 | -0.5% | $15.56 | $16.05 | $15.05 | 3,785,400 |
- Ticker
- NASDAQ:CCXI
- Asset type
- Stock
- Sector
- Financials
- Industry
- Shell companies & SPACs
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 2, 2026
Churchill Capital Corp XI Shareholders Approve Business Combination with Agility Robotics
Latest news
Churchill Capital Corp XI Shareholders Approve Business Combination with Agility Robotics
Nov 2, 2026
Closed $10.69 (+15.1%) on Nov 3, 2026
Agility Robotics and Churchill Capital Corp XI S-4 Registration Statement Declared Effective by SEC in Connection with Proposed Business Combination
Oct 13, 2026
Closed $10.83 (-3.0%) on Oct 14, 2026
Issued by another party
Agility Robotics and Churchill Capital Corp XI Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Jul 14, 2026
Closed $15.97 (+11.4%) on Jul 14, 2026
Issued by another party
Agility Robotics to Go Public Through $2.5 Billion Merger with Churchill Capital Corp XI
Jun 24, 2026
Closed $11.99 (+15.1%) on Jun 24, 2026
Issued by another party
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
Aug 24, 2022
ChemoCentryx Inc. on 6ix
- Sector
- Financials
- Industry
- Shell companies & SPACs
- News releases
- 5 in the last 12 months · 46 in all · newest Nov 2, 2026 · oldest 2019
- Calls
- 5 calls with a replay · 5 with a transcript · latest May 5, 2022
- Decks
- 1 deck · latest Jan 16, 2020
Where ChemoCentryx Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CCXI · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CCXI | BOATS | United States | USD |
| NASDAQ:CCXIU | NASDAQ | United States | USD |
Valuation
Statements: 4 quarters to Jun 30, 2026 · price Nov 4, 2026
- Enterprise value
- $470.5M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.21
Shell companies & SPACs: the 10 companies nearest in size, of 285 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ChemoCentryx Inc. · NASDAQ:CCXI | US$471.8M | US$470.5M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 1.21 |
| EQV Ventures Acquisition Corp. II · NYSE:EVAC | US$489.7M | US$488.8M | 29.7× | n/a | n/a | n/a | n/a | n/a | 0.00 |
| Bain Capital GSS Investment Corp. · NYSE:BCSS | US$481.2M | US$481.2M | 29.2× | n/a | n/a | n/a | n/a | n/a | 0.04 |
| B&R Technology Merger Corp. · NASDAQ:BRTM | US$479.2M | US$478.3M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cantor Equity Partners IV, Inc. · NASDAQ:CEPF | US$474.1M | US$474.1M | 28.5× | n/a | n/a | n/a | n/a | n/a | 0.02 |
| General Catalyst Global Resilience Merger Corp. · NASDAQ:GCGR | US$460.0M | US$459.5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Churchill Capital Corp XII · NASDAQ:CXII | US$430.7M | US$429.3M | 74.9× | n/a | n/a | n/a | n/a | n/a | n/a |
| K&F Growth Acquisition Corp. II · NASDAQ:KFII | US$416.5M | US$416.5M | 42.0× | n/a | n/a | n/a | n/a | n/a | -0.03 |
| Ares Acquisition Corp. III · NYSE:AAC | US$391.1M | US$389.1M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Keystone Acquisition Corp. · NASDAQ:KEYY | US$381.0M | US$380.1M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gores Holdings X, Inc. · NASDAQ:GTEN | US$377.1M | US$377.0M | 36.6× | n/a | n/a | n/a | n/a | n/a | 0.02 |
| Median of the others | US$445.3M | US$444.4M | 33.2× | 0.02 |
Events
| Call | When | Status |
|---|---|---|
| ChemoCentryx (NASDAQ:CCXI) Q1 2022 Earnings Call | Thu, May 05, 2022 · 5:00 PM ET | Replay |
| ChemoCentryx (NASDAQ:CCXI) Q4 2021 Earnings Call | Tue, Mar 01, 2022 · 5:00 PM ET | Replay |
| ChemoCentryx (NASDAQ:CCXI) Q3 2021 Earnings Call | Tue, Nov 09, 2021 · 5:00 PM ET | Replay |
| ChemoCentryx (NASDAQ:CCXI) Q2 2021 Earnings Call | Mon, Aug 09, 2021 · 5:00 PM ET | Replay |
| ChemoCentryx (NASDAQ:CCXI) Q3 2020 Earnings Call | Mon, Nov 09, 2020 · 5:00 PM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2020) | Investor deck | 38 slides | Jan 16, 2020 |
Financials
Annual, in USD
Income statement
| Line | FY2025 |
|---|---|
| Operating income | -167.7K |
| Income before tax | 382.1K |
| Net income | 382.1K |
| Earnings per share, basic | 0.01 |
Balance sheet
| Line | FY2025 |
|---|---|
| Cash and equivalents | 736.2K |
| Current assets | 1.06M |
| Total assets | 415.9M |
| Current liabilities | 130.7K |
| Total liabilities | 16.1M |
| Shareholders' equity | 399.8M |
| Shares outstanding | 55.7M |
Cash flow
| Line | FY2025 |
|---|---|
| Cash from operations | -632.8K |
| Capital spending | -4 |
| Free cash flow | -632.8K |
| Cash from investing | -414.0M |
| Cash from financing | 415.4M |
| Change in cash | 736.2K |
Cap table
Built by 6ix from ChemoCentryx Inc.’s releases
- Common shares
- 41,900,000
- Fully diluted
- 41,900,000
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 41,900,000 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 41,900,000 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Michael Klein Other companies: Churchill Capital Corp. XIII (See Remarks, Director · Since at least Jul 30, 2026); Churchill Capital Corp XII (See Remarks, Director · Since at least Apr 27, 2026); Agility Robotics, Inc. (See Remarks, Director · Since at least Dec 16, 2025); Infleqtion, Inc. (See Remarks, Director · Since at least May 13, 2025); Oklo Inc. (Board Member · Since at least Jul 7, 2021); Claritev Corporation (Director · Since at least Feb 13, 2020); Skillsoft Corp. (Director · Since at least Jun 26, 2019); Churchill Capital Corp VII (See Remarks, Director · Feb 11, 2021 – Feb 11, 2021 · Past); Churchill Capital VI Corp (See Remarks, Director · Feb 11, 2021 – Feb 11, 2021 · Past); Churchill Capital V Corp (See Remarks, Director · Dec 15, 2020 – Dec 15, 2020 · Past); Lucid Group, Inc. (See Remarks, Director · Jul 29, 2020 – Jul 29, 2020 · Past); Gordon Pointe Acquisition Corp (Director · Jul 1, 2020 – Jul 22, 2020 · Past); IHS Holding Limited (Director · Dec 1, 2008 – Apr 10, 2013 · Past); Citigroup, Inc. (Co-CEO Citi Markets & Banking · Feb 1, 2007 – Jan 22, 2008 · Past) | See Remarks, Director · Since at least Nov 2, 2026 |
| David E. Wheadon Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); Supernus Pharmaceuticals, Inc. (Director · Since at least Jan 1, 2026); Vaxart, Inc. (Director · Since at least Aug 4, 2022); Sotera Health Company (Director · Since at least May 27, 2022); Karuna Therapeutics Inc (Director · Jun 15, 2022 – Mar 18, 2024 · Past) | Director · May 26, 2022 – Oct 20, 2022 · Past |
| Henry A McKinnell Other companies: Federal Street Acquisition Corp (Director · Jul 13, 2017 – Jan 4, 2019 · Past); Optimer Pharmaceuticals Inc (CEO and Chairman of the Board, Director · Jan 10, 2011 – Oct 24, 2013 · Past); Angiotech Pharmaceuticals Inc (Director · May 12, 2008 – Dec 10, 2009 · Past); Moody's Corporation (Director · Feb 8, 2006 – Mar 18, 2021 · Past); Exxon Mobil Corporation (Director · Dec 30, 2005 – May 30, 2007 · Past); Pfizer, Inc. (Director · Dec 30, 2005 – Feb 28, 2007 · Past) | Director · Oct 17, 2016 – May 20, 2022 · Past |
| James L. Tyree Other companies: Genelux Corporation (Lead Independent Director · Since at least Jan 25, 2023); Assertio Holdings, Inc. (Director · May 19, 2020 – Mar 14, 2024 · Past); Depomed Inc (Director · Oct 17, 2016 – May 8, 2018 · Past); Innoviva, Inc. (Director · Jun 2, 2014 – Apr 20, 2017 · Past); Abbott Laboratories (Executive Vice President · Feb 14, 2006 – Feb 27, 2009 · Past) | Director · Jun 5, 2012 – Oct 20, 2022 · Past |
| Rishi Gupta Other companies: Turnstone Biologics Corp. (Director · Since at least Jul 20, 2023); Enliven Therapeutics, Inc. (Member of the Board of Directors · Since at least Feb 23, 2023); Verona Pharma plc (Director · Jan 1, 2021 – May 11, 2023 · Past); Dimension Therapeutics (Director · Oct 21, 2015 – May 19, 2016 · Past); Sientra Inc (Director · Oct 28, 2014 – Oct 28, 2014 · Past) | Director · Feb 8, 2012 – Jun 22, 2012 · Past |
| William C. Fairey Other companies: Ascendis Pharma A/S (Director · Since at least Mar 18, 2026); KalVista Pharmaceuticals, Inc. (Director · Since at least Apr 18, 2024); Rein Therapeutics, Inc. (Director · Since at least Oct 31, 2023); Mirum Pharmaceuticals, Inc. (Director · Since at least Aug 19, 2021); MyoKardia Inc (EVP, Chief Commercial Officer · Jan 28, 2019 – Nov 17, 2020 · Past) | Chief Operating Officer · Jan 3, 2018 – Jan 3, 2018 · Past |
| Anne-Marie Duliege Other companies: Rigel Pharmaceuticals, Inc. (EVP & Chief Medical Officer · Mar 7, 2016 – Mar 20, 2019 · Past); Affymax Inc (Chief Medical Officer · Jan 1, 2008 – Jan 30, 2013 · Past) | EVP, Chief of Strategic Dev. · Mar 25, 2014 – Nov 18, 2014 · Past |
| Edward Penhoet Other companies: Immune Design Corp (Director · Jul 23, 2014 – Apr 2, 2019 · Past); Scynexis, Inc. (Director · May 2, 2014 – Jun 4, 2015 · Past) | Director · Feb 8, 2012 – May 23, 2013 · Past |
| Joseph M Feczko Other companies: Keryx Biopharmaceuticals Inc (Director · Jul 16, 2010 – Jun 17, 2015 · Past); Pfizer, Inc. (Senior Vice President · Dec 30, 2005 – Mar 13, 2009 · Past) | Director · Apr 25, 2012 – Oct 20, 2022 · Past |
| Jennifer Lyn Herron Other companies: Ariad Pharmaceuticals Inc (Exec V.P. Chief Comm'l Officer · May 31, 2016 – Feb 16, 2017 · Past) | Director · Jun 28, 2022 – Oct 20, 2022 · Past |
All 20 people
| Person | Seat |
|---|---|
| Juan Jaen Other companies: Arcus Biosciences, Inc. (President · Since at least Mar 14, 2018) | SVP, Drug Discovery & CSO · Feb 8, 2012 – Jul 23, 2013 · Past |
| Roger C Lucas Other companies: Bio-Techne Corp (Director · Feb 1, 2006 – Oct 10, 2017 · Past) | Director · Feb 8, 2012 – Mar 5, 2019 · Past |
| Thomas J Schall Other companies: Immuneering Corporation (Director · Since at least Mar 11, 2024) | President and CEO, Director · Feb 8, 2012 – Oct 20, 2022 · Past |
| Israel Charo | SVP, Research · Sep 17, 2014 – Sep 18, 2014 · Past |
| Markus J Cappel | Chief Bus. Officer & Treasurer · Feb 8, 2012 – Oct 20, 2022 · Past |
| Pui San Kwan | Principal Acctg Officer · Mar 5, 2018 – Feb 25, 2021 · Past |
| Rajinder Singh | SVP, Research · Apr 15, 2019 – Apr 15, 2019 · Past |
| Susan M Kanaya | See Remarks, Director · Feb 8, 2012 – Oct 20, 2022 · Past |
| Tausif Butt | EVP, Chief Operating Officer · Feb 23, 2021 – Oct 20, 2022 · Past |
| Thomas A Edwards | Director · Jul 28, 2015 – Oct 20, 2022 · Past |
Log in to ask 6ix AI your own questions about ChemoCentryx Inc.